Italy revokes marketing approval for Amlodipine/Valsartan/Hydrochlorothiazide Mylan Pharma
Italy's medicines agency AIFA has published an official notice on 3 November 2026 confirming that the marketing permission for the blood pressure medicine Amlodipine/Valsartan/Hydrochlorothiazide Mylan Pharma has been revoked. The license holder asked for the cancellation and voluntarily gave up the authorization. Marketing authorization is the official permission that lets a medicine be sold in a country.
This summary was generated by AI; the official source prevails.
What does it mean?
Italy's medicines regulator has officially ended the permission to sell a combination blood pressure pill made by Mylan Pharma. The company itself asked for this, so the pill is no longer approved for sale in Italy.
Who is affected?
Patients in Italy who take this combination blood pressure medicine and pharmacies that supply it.
What changes?
Before, the medicine Amlodipine/Valsartan/Hydrochlorothiazide Mylan Pharma was authorized for sale in Italy; now its marketing permission has been revoked.